Sökning: id:"swepub:oai:DiVA.org:uu-224999" >
Population pharmaco...
-
Zvada, Simbarashe P.
(författare)
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis : in silico evaluation of currently recommended doses
- Artikel/kapitelEngelska2014
Förlag, utgivningsår, omfång ...
-
2014-01-31
-
Oxford University Press (OUP),2014
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-224999
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-224999URI
-
https://doi.org/10.1093/jac/dkt524DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
To describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children and evaluate the adequacy of steady-state exposures. We used previously published data for 76 South African children with tuberculosis to describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid. Monte Carlo simulations were used to predict steady-state exposures in children following doses in fixed-dose combination tablets in accordance with the revised guidelines. Reference exposures were derived from an ethnically similar adult population with tuberculosis taking currently recommended doses. The final models included allometric scaling of clearance and volume of distribution using body weight. Maturation was included for clearance of isoniazid and clearance and absorption transit time of rifampicin. For a 2-year-old child weighing 12.5 kg, the estimated typical oral clearances of rifampicin and pyrazinamide were 8.15 and 1.08 L/h, respectively. Isoniazid typical oral clearance (adjusted for bioavailability) was predicted to be 4.44, 11.6 and 14.6 L/h for slow, intermediate and fast acetylators, respectively. Higher oral clearance values in intermediate and fast acetylators also resulted from 23 lower bioavailability compared with slow acetylators. Simulations based on our models suggest that with the new WHO dosing guidelines and utilizing available paediatric fixed-dose combinations, children will receive adequate rifampicin exposures when compared with adults, but with a larger degree of variability. However, pyrazinamide and isoniazid exposures in many children will be lower than in adults. Further studies are needed to confirm these findings in children administered the revised dosages and to optimize pragmatic approaches to dosing.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Denti, Paolo
(författare)
-
Donald, Peter R.
(författare)
-
Schaaf, H. Simon
(författare)
-
Thee, Stephanie
(författare)
-
Seddon, James A.
(författare)
-
Seifart, Heiner I.
(författare)
-
Smith, Peter J.
(författare)
-
McIlleron, Helen M.
(författare)
-
Simonsson, Ulrika S. H.Uppsala universitet,Institutionen för farmaceutisk biovetenskap,farmakometri(Swepub:uu)usv12211
(författare)
-
Uppsala universitetInstitutionen för farmaceutisk biovetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Antimicrobial Chemotherapy: Oxford University Press (OUP)69:5, s. 1339-13490305-74531460-2091
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Zvada, Simbarash ...
-
Denti, Paolo
-
Donald, Peter R.
-
Schaaf, H. Simon
-
Thee, Stephanie
-
Seddon, James A.
-
visa fler...
-
Seifart, Heiner ...
-
Smith, Peter J.
-
McIlleron, Helen ...
-
Simonsson, Ulrik ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Farmaceutiska ve ...
- Artiklar i publikationen
-
Journal of Antim ...
- Av lärosätet
-
Uppsala universitet